Association between CYP3A5 genotype and overall survival in high-risk early stage breast cancer patients receiving cyclophosphamide-based therapy.
Publication
, Conference
Petros, W; Broadwater, G; Colvin, M; Marcom, PK; Chao, N; Marks, J
Published in: BREAST CANCER RESEARCH AND TREATMENT
January 1, 2006
Duke Scholars
Published In
BREAST CANCER RESEARCH AND TREATMENT
ISSN
0167-6806
Publication Date
January 1, 2006
Volume
100
Start / End Page
S277 / S277
Location
San Antonio, TX
Publisher
SPRINGER
Conference Name
29th Annual San Antonio Breast Cancer Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Petros, W., Broadwater, G., Colvin, M., Marcom, P. K., Chao, N., & Marks, J. (2006). Association between CYP3A5 genotype and overall survival in high-risk early stage breast cancer patients receiving cyclophosphamide-based therapy. In BREAST CANCER RESEARCH AND TREATMENT (Vol. 100, pp. S277–S277). San Antonio, TX: SPRINGER.
Petros, W., G. Broadwater, M. Colvin, P. K. Marcom, N. Chao, and J. Marks. “Association between CYP3A5 genotype and overall survival in high-risk early stage breast cancer patients receiving cyclophosphamide-based therapy.” In BREAST CANCER RESEARCH AND TREATMENT, 100:S277–S277. SPRINGER, 2006.
Petros W, Broadwater G, Colvin M, Marcom PK, Chao N, Marks J. Association between CYP3A5 genotype and overall survival in high-risk early stage breast cancer patients receiving cyclophosphamide-based therapy. In: BREAST CANCER RESEARCH AND TREATMENT. SPRINGER; 2006. p. S277–S277.
Petros, W., et al. “Association between CYP3A5 genotype and overall survival in high-risk early stage breast cancer patients receiving cyclophosphamide-based therapy.” BREAST CANCER RESEARCH AND TREATMENT, vol. 100, SPRINGER, 2006, pp. S277–S277.
Petros W, Broadwater G, Colvin M, Marcom PK, Chao N, Marks J. Association between CYP3A5 genotype and overall survival in high-risk early stage breast cancer patients receiving cyclophosphamide-based therapy. BREAST CANCER RESEARCH AND TREATMENT. SPRINGER; 2006. p. S277–S277.
Published In
BREAST CANCER RESEARCH AND TREATMENT
ISSN
0167-6806
Publication Date
January 1, 2006
Volume
100
Start / End Page
S277 / S277
Location
San Antonio, TX
Publisher
SPRINGER
Conference Name
29th Annual San Antonio Breast Cancer Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences